JP Morgan Chase
JANX icon

JP Morgan Chase’s Janux Therapeutics JANX Stock Holding History

JP Morgan Chase’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.74M Sell
178,535
-50,733
-22% -$735K ﹤0.01% 3951
2026
Q1 		$2.99M Buy
229,268
+58,759
+34% +$806K ﹤0.01% 3779
2025
Q4 		$2.35M Sell
170,509
-38,674
-18% -$910K ﹤0.01% 3959
2025
Q3 		$5.11M Sell
209,183
-38,241
-15% -$931K ﹤0.01% 3342
2025
Q2 		$5.72M Buy
247,424
+112,116
+83% +$2.95M ﹤0.01% 3026
2025
Q1 		$3.65M Sell
135,308
-56,295
-29% -$2.12M ﹤0.01% 3416
2024
Q4 		$10.3M Buy
191,603
+173,211
+942% +$9.16M ﹤0.01% 2667
2024
Q3 		$836K Sell
18,392
-821
-4% -$35.7K ﹤0.01% 4583
2024
Q2 		$805K Sell
19,213
-130
-0.7% -$6.1K ﹤0.01% 4409
2024
Q1 		$728K Buy
19,343
+1,607
+9% +$35K ﹤0.01% 4553
2023
Q4 		$190K Sell
17,736
-130,873
-88% -$1.13M ﹤0.01% 5410
2023
Q3 		$1.5M Sell
148,609
-4,827
-3% -$55.7K ﹤0.01% 3780
2023
Q2 		$1.82M Buy
153,436
+23,779
+18% +$318K ﹤0.01% 3605
2023
Q1 		$1.57M Buy
129,657
+25,874
+25% +$431K ﹤0.01% 3709
2022
Q4 		$1.37M Sell
103,783
-1,270
-1% -$18.6K ﹤0.01% 3850
2022
Q3 		$1.42M Buy
105,053
+1,575
+2% +$21K ﹤0.01% 3747
2022
Q2 		$1.26M Buy
103,478
+85,552
+477% +$1.01M ﹤0.01% 3907
2022
Q1 		$256K Buy
17,926
+4,638
+35% +$75.9K ﹤0.01% 5060
2021
Q4 		$262K Buy
13,288
+6,814
+105% +$143K ﹤0.01% 5200
2021
Q3 		$140K Buy
6,474
+5,828
+902% +$168K ﹤0.01% 5403
2021
Q2 		$16K Buy
+646
New +$14.4K ﹤0.01% 5969

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

JP Morgan Chase's JANX Position: Q2 2026 in Review

JP Morgan Chase reduced its Janux Therapeutics (JANX) stake by 22% in Q2 2026, selling an estimated $735K and leaving 178,535 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #3951.

JP Morgan Chase first reported a position in JANX in Q2 2021 and has held it in 21 quarters since. The position peaked at $10.3M in Q4 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • JP Morgan Chase held 178,535 shares of Janux Therapeutics worth $2.74M as of Q2 2026.
  • JP Morgan Chase sold 50,733 Janux Therapeutics shares in Q2 2026, an estimated $735K.
  • Janux Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3951 holding.
  • JP Morgan Chase first reported a position in Janux Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • JP Morgan Chase's Janux Therapeutics position peaked at $10.3M in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.